Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCT-194
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
BCT-194 is a small molecule drug developed by Novartis as a topical cream for the treatment of psoriasis. It acts as an inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), a target involved in inflammatory signaling pathways. The drug was investigated primarily for immune system and skin diseases, with clinical trials reaching Phase 1 for psoriasis. Its mechanism of action is to inhibit p38 MAPK, which may reduce inflammation associated with psoriatic lesions. As of the latest updates, development has not progressed beyond early clinical studies and there are no approved indications or brand names associated with this compound[1][2][3].
02
Targets
MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on BCT-194.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCT-194.